Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy

Life Sciences

Volumn 82, Issue 11-12, 2008, Pages 570-576

  Sharma, Shyam S ^a   Kumar, Ashutosh ^a   Kaundal, Ravinder K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

4 ANI; Diabetic neuropathy; Neuropathic pain; PARP

Indexed keywords

4 AMINO 1,8 NAPHTHALIMIDE; NAPHTHALENE DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; ENZYME ACTIVATION; IMMUNOREACTIVITY; MALE; MOTOR NERVE CONDUCTION; NERVE BLOOD FLOW; NOCICEPTION; NONHUMAN; PATHOGENESIS; RAT; STREPTOZOCIN DIABETES; TAIL FLICK TEST;

1-NAPHTHYLAMINE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; HUMANS; MALE; NAD; NAPHTHALIMIDES; NEURAL CONDUCTION; PAIN MEASUREMENT; POLY(ADP-RIBOSE) POLYMERASES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

ANIMALIA; RATTUS;

EID: 39749182775     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.11.031     Document Type: Article

References (46)

1. Adaikalakoteswari A., Rema M., Mohan V., and Balasubramanyam M. Oxidative DNA damage and augmentation of poly(ADP-ribose) polymerase/nuclear factor-kappa B signaling in patients with Type 2 diabetes and microangiopathy. The International Journal of Biochemistry & Cell Biology 39 (2007) 1673-1684
2. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes research and clinical practice 67 1 (2005) 3-21
3. Banasik M., Komura H., Shimoyama M., and Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. The Journal of Biological Chemistry 267 3 (1992) 1569-1575
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 6865 (2001) 813-820
5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 6 (2005) 1615-1625
6. Calcutt N.A. Modeling diabetic sensory neuropathy in rats. Methods in Molecular Medicine 99 (2004) 55-65
7. Cameron N.E., and Cotter M.A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 46 (1997) S31-S37
8. Cameron N.E., Cotter M.A., Horrobin D.H., and Tritschler H.J. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 41 4 (1998) 390-399
9. Coppey L.J., Gellett J.S., Davidson E.P., Dunlap J.A., Lund D.D., and Yorek M.A. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50 8 (2001) 1927-1937
10. Cotter M.A., Love A., Watt M.J., Cameron N.E., and Dines K.C. Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia 38 11 (1995) 1285-1294
11. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., and Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. The Journal of Clinical Investigation 112 (2003) 1049-1057
12. Graziani G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacological Research 52 (2005) 109-118
13. Ilnytska O., Lyzogubov V.V., Stevens M.J., Drel V.R., Mashtalir N., Pacher P., Yorek M.A., and Obrosova I.G. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 55 6 (2006) 1686-1694
14. Jensen T.S., Gottrup H., Sindrup S.H., and Bach F.W. The clinical picture of neuropathic pain. European Journal of Pharmacology 429 1-3 (2001) 1-11
15. Kabra D.G., Thiyagarajan M., Kaul C.L., and Sharma S.S. Neuroprotective effect of 4-amino-1,8-napthalimide, a poly(ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat. Brain Research Bulletin. 62 5 (2004) 425-433
16. Kumar A., Kaundal R.K., Iyer S., and Sharma S.S. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sciences 80 13 (2007) 1236-1244
17. Li F., Szabo C., Pacher P., Southan G.J., Abatan O.I., Charniauskaya T., Stevens M.J., and Obrosova I.G. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 47 4 (2004) 710-717
18. Low P., and Dotson R. Symptom treatment of painful neuropathy. The Journal of American Medical Association 280 (1998) 1863-1864
19. Nickander K.K., McPhee B.R., Low P.A., and Tritschler H. Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radical Biology & Medicine 21 5 (1996) 631-639
20. Nisselbaum J.S., and Green S. A simple ultramicro method for determination of pyridine nucleotides in tissue. Analytical Biochemistry 27 (1969) 212-217
21. Obrosova I.G., Li F., Abatan O.I., Forsell M.A., Komjati K., Pacher P., Szabo C., and Stevens M.J. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53 3 (2004) 711-720
22. Obrosova I.G., Drel R.V., Pacher P., Ilyatska O., Wang Z.Q., Stevans M.J., and Yorek M.A. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy. Diabetes 54 (2005) 3435
23. Pacher P., Liaudet L., Soriano F.G., Mabley J.G., Szabo E., and Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51 2 (2002) 514-521
24. Pacher P., Obrosova I.G., Mabley J.G., and Szabo C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Current Medicinal Chemistry 12 3 (2005) 267-275
25. Patel T., and Gores G.J. Inhibition of bile-salt-induced hepatocyte apoptosis by the antioxidant lazaroid U83836E. Toxicology & Applied Pharmacology. 142 1 (1997) 116-122
26. Plummer E.R. Inhibition of poly(ADP-ribose) polymerase in cancer. Current Opinion in Pharmacology 6 (2006) 364-368
27. Pop-Busui R., Marinescu V., Van Huysen C., Li F., Sullivan K., Greene D.A., Larkin D., and Stevens M.J. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-l-carnitine administration. Diabetes 51 8 (2002) 2619-2628
28. Pop-Busui R., Sima A., and Stevens M.J. Diabetic neuropathy and oxidative stress. Diabetes/Metabolism Research & Reviews 22 4 (2006) 257-273
29. Purves T., Middlemas A., Agthong S., Jude E.B., Boulton A.J., Fernyhough P., and Tomlinson D.R. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. Faseb J 15 13 (2001) 2508-2514
30. Sayyed S.G., Kumar A., and Sharma S.S. Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy. Life Sciences 79 8 (2006) 777-783
31. Sharma S.S., and Sayyed S.G. Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy. Clinical and Experimental Pharmacology and Physiology 33 (2006) 1022-1028
32. Sharma S.S., Munusamy S., Thiyagarajan M., and Kaul C.L. Neuroprotective effect of peroxynitrite decomposition catalyst and poly(adenosine diphosphate-ribose) polymerase inhibitor alone and in combination in rats with focal cerebral ischemia. Journal of Neurosurgery 101 4 (2004) 669-675
33. Sima A.A. New insights into the metabolic and molecular basis for diabetic neuropathy. Cellular and Molecular Life Sciences 60 11 (2003) 2445-2464
34. Sima A.A. Pathological mechanisms involved in diabetic neuropathy: can we slow the process?. Current Opinion in Investigational Drugs 7 4 (2006) 324-337
35. Soriano G.F., Pacher P., Mabley J., Liaudet L., and Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circulation Research 89 (2001) 684-691
36. Soriano G.F., Virag L., Jagtap P., Szabo E., Mabley J.G., Liaudet L., Marton A., Hoyt D.G., Murthy K.G., Salzman A.L., Southan G.J., and Szabo C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Medicine 7 (2001) 108-113
37. Stevens M.J., Obrosova I., Cao X., Van Huysen C., and Greene D.A. Effects of dl-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49 6 (2000) 1006-1015
38. Stevens M.J., Li F., Drel V.R., Abaton O.I., Kim H., Burnett D., Larkin D., and Obrosova I.G. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. The Journal of Pharmacology and Experimental Therapeutics 320 1 (2007) 458-464
39. Sweitzer S.M., Medicherla S., Almirez R., Dugar S., Chakravarty S., Shumilla J.A., Yeomans D.C., and Protter A.A. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 109 3 (2004) 409-419
40. Vareniuk I., Pavlov I.A., Drel V.R., Lyzogubov V.V., Ilnytska O., Bell S.R., Tibrewala J., Groves J.T., and Obrosova I.G. Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Experimental Neurology 205 2 (2007) 425-436
41. Vincent A.M., Russell J.W., Low P., and Feldman E.L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine Reviews 25 4 (2004) 612-628
42. Vinik, A.I., 2000. Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 43, 957-973.
43. Vinik A.I. Advances in diabetes for the millennium: new treatments for diabetic neuropathies. MedGenMed. 6 3 (2004) 13
44. Virag L., and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacological Reviews 54 3 (2002) 375-429
45. Wada R., and Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Annals of New York Academy of Sciences 1043 (2005) 598-604
46. www.who.int/int/medicenter/factsheet/fs236/em/04/20/2007